Pharma funds
Executive Summary
Drug companies and their trade groups employed 1,100 lobbyists and spent $155 million on federal lobbying efforts last year, according to the Center for Public Integrity. Topping any single company, PhRMA spent more than $18 million on lobbying last year and $104 million since 1998. Meanwhile, BIO spent $5.4 million last year and almost $35 million in the same nine-year span. Pfizer spent $12 million last year, more than any other firm. In comparison, Amgen spent over $10 million, Sanofi spent $6.7 million, and Merck spent just over $4 million...
You may also be interested in...
Moderna Stands Alone With Single-Antigen Approach To COVID-19 Vaccine
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Kansas City TCM Firm Persists With COVID-19 Claims Following US Regulators' Warning
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.
Coronavirus Update: The Hunt For A Vaccine & Non-COVID-19 Trial Plans Go Awry
In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into the impact on biopharma commercial activities.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: